A curated listing of global health funding opportunities.
About
Funding to develop and test novel therapeutics, medical devices, diagnostics.You can apply for academically-led translational projects that aim to either:
- improve prevention, diagnosis, prognosis or treatment of significant health needs;
- develop research tools that increase the efficiency of developing interventions.
Criteria
- Total fund: £11,000,000
- Deadline: 19 November 2025, 4:00pm UK time
- Criteria: employment at a research organisation eligible for MRC funding.
Apply to the MRC: Developmental Pathway Funding scheme
This is a new ODA-funded opportunity to contract a high-quality research partnership to collaborate with the UK Health Security Agency to deliver the UK Public Health Rapid Support Team (UK-PHRST).
The UK-PHRST works to address the threat posed by infectious disease outbreaks in LMICs through an integrated triple remit incorporating outbreak response, research, and capacity-building. The primary aim of the Research Partnership is to deliver an interdisciplinary programme of planned and responsive research that aims to support and improve public health responses to infectious disease outbreaks in the world’s poorest countries while generating evidence for best practice in outbreak response, facilitating its uptake into public health policy, and supporting continuous learning to improve future UK-PHRST deployments.
Criteria
The application must make a clear case for how the research will be of primary benefit to the development challenges of LMICs and how outcomes will promote health and welfare. The lead applicant must be employed by a research active higher education institution (HEI) based in the UK and there must be at least one co-applicant employed by a research active HEI or research institute based in an ODA-eligible country.
Amount
Funding is a single award of up to £18 million (£3.6 million per year) for five years.
Deadline
13:00 GMT, 27 November 2025
About
This year’s programme will reflect the field’s growing complexity and dynamic response to the global health challenge of antimicrobial resistance (AMR). It will highlight surveillance innovations, novel therapeutics, pioneering anti-AMR strategies, advances in point-of-care technologies and diagnostics, the variety of non-susceptibility phenotypes, and lessons learned from non-bacterial microorganisms. The role of big data and emerging technologies in driving insights and accelerating progress across these areas will also be a key theme.
This conference will be a hybrid meeting – with onsite or virtual attendance. In addition to invited talks from global leaders, the programme will include short oral presentations selected from abstracts, posters, poster pitch talks and networking opportunities.
criteria
- Priority will be given to PhD students/trainees from LMICs, or those from underrepresented/minority groups. Other early career researchers will be considered if funds allow.
- Deadline for bursary application: 1 December 2025.